Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Methylphenidate
Ritalin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | ACTIVE_COMPARATOR | Concerta one 54mg tablet once |
| 002 | ACTIVE_COMPARATOR | Ritalin-SR 3-20mg tablets once |
| 003 | ACTIVE_COMPARATOR | Novo-Methylphenidate ER-C one 54mg tablet once |
| Name | Type | Description |
|---|---|---|
| Ritalin-SR | DRUG | 3-20mg tablets, once |
| Concerta | DRUG | one 54mg tablet, once |
| Novo-Methylphenidate ER-C | DRUG | one 54mg tablet, once |
Inclusion Criteria: * The volunteer will be assessed against all protocol specified criteria at investigator site: If a female, must be postmenopausal (no spontaneous menses for at least 2 years), surgically sterile, abstinent or, if sexually active, be practicing an effective method of birth contr...
Methylphenidate is a small molecule being studied for use in Attention Deficit Disorder With Hyperactivity, Major Depressive Disorder, Parkinson Disease, and pharmacokinetic studies in healthy volunteers. It is an investigational drug in clinical development, with trials conducted by Johnson & Johnson.
Methylphenidate is a central nervous system stimulant. It is being studied for its effects on attention, depression, and apathy in Parkinson's disease. The specific molecular target is not disclosed in the available information.
Methylphenidate is being developed by Johnson & Johnson, a company traded under the ticker JNJ. The company is conducting clinical trials to evaluate the drug's safety and effectiveness across several indications.
Methylphenidate is in Phase 1 clinical development, according to the latest data. It has completed Phase 3 trials for Attention Deficit Disorder With Hyperactivity and Major Depressive Disorder, and a Phase 2 trial for Parkinson Disease is planned.
Methylphenidate has been studied in several clinical trials. NCT00246220 was a completed Phase 3 trial in adults with ADHD, NCT00246233 was a completed Phase 3 trial for Major Depressive Disorder, and NCT01118702 was a Phase 1 pharmacokinetic study in healthy volunteers. A Phase 2 trial, NCT05669170, is planned for apathy in Parkinson's disease.
Methylphenidate is the active ingredient in the brand-name drug CONCERTA. Clinical trials have evaluated both Methylphenidate and CONCERTA (methylphenidate hydrochloride) for conditions such as ADHD and Major Depressive Disorder.